Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia

Mediators of Inflammation

Volumn 2006, Issue , 2006, Pages

  Wołowiec, Dariusz ^a   Dybko, Jarosław ^a   Wróbel, Tomasz ^a   Urbaniak Kujda, Donata ^a   Jaźwiec, Bozena ^a   Tomaszewska Toporska, Beata ^a   Kapelko Słowik, Katarzyna ^a   Potoczek, Stanisław ^a   Kuliczkowski, Kazimierz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BETA 2 MICROGLOBULIN; CYTOKINE; ENDOSTATIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; PROTEOHEPARAN SULFATE; SYNDECAN 1; VASCULOTROPIN; FIBROBLAST GROWTH FACTOR 2; MEMBRANE PROTEIN; PROTEOGLYCAN; SDC1 PROTEIN, HUMAN; SYNDECAN; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROGNOSIS; B CELL LEUKEMIA; BLOOD; MIDDLE AGED; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; ENDOSTATINS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROTEOGLYCANS; SYNDECAN-1; SYNDECANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646384921     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI/2006/42394     Document Type: Article

References (30)

1. E Ruoslahti Y Yamaguchi Proteoglycans as modular of growth factor activities. Cell 64 1991 867 869
2. M Bernfield R Kokenyesi M Kato Biology of the sydecans: a family of four transmembrane heparan sulphate proteoglycans. Annual Review of Cell Biology 8 1993 365 393
3. K Elenius M Jalkanen Function of the syndecans: a family of cell surface proteoglycans. Journal of Cell Science 107 1994 11 2975 2982 7698997
4. R D Sanderson P Lalor M Bernfield B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regulation 1 1989 1 27 35 2519615
5. M V Dhodapkar T Kelly A Theus A B Athota B Barlogie R D Sanderson Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. British Journal of Haematology 99 1997 2 368 371
6. M V Dhodapkar E Abe A Theus Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 91 1998 8 2679 2688
7. R C Ridley H Xiao H Hata J Woodlif J Epstein R D Sanderson Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81 1993 3 767 774
8. C Seidel A Sundan M Hjorth Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95 2000 2 388 392
9. A Sebestyen L Berczi R Mihalik S Paku A Matolcsy L Kopper Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas. British Journal of Haematology 104 1999 2 412 419 10050727
10. T E Witzig T Kimlinger M Stenson T Therneau Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma 31 1998 1-2 167 175
11. B D Cheson J M Bennett M Grever National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 1996 12 4990 4997
12. F Bertolini f.bertolini@agora.stm.it M Paolucci F Peccatori Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. British Journal of Haematology 106 1999 2 504 509
13. C Basilico D Moscatelli The FGF family of growth factors and oncogenes. Advances in Cancer Research 59 1992 115 165
14. A Bikfalvi Z C Han Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia 8 1994 3 523 529
15. A Konig T Menzel S Lynen Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11 1997 2 258 265 9009090
16. O Bairey obairey@post.tau.ac.il Y Zimara M Shaklai E Rabizadeh Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. British Journal of Haematology 113 2001 2 400 406 11380405
17. S Duensing J Atzpodien Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia. Blood 85 1995 7 1978 1979
18. I Christiansen C Gidlof A Wallgren B Simonsson T H Tottermann Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. Blood 84 1994 9 3010 3016 7949173
19. S Molica A Vacca D Ribatti Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 100 2002 9 3344 3351
20. S Molica smolica@libero.it G Vitelli D Levato A Ricciotti G Digiesi Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. British Journal of Cancer 86 2002 1 31 35
21. A Aguayo H Kantarjian T Manshouri Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96 2000 6 2240 2245 10979972
22. H Chen A T Treeweeke D C West In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 96 2000 9 3181 3187
23. A R Kini N E Kay L C Peterson Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 14 2000 8 1414 1418
24. S Molica molica@voyager.it G Vitelli D Levato G M Gandolfo V Liso Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. British Journal of Haematology 107 1999 3 605 610
25. M O'Reilly T Boehm Y Shing Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 1997 2 277 285
26. A L Feldman H Pak J C Yang H R Jr Alexander S K Libutti steven_libutt@nih.gov Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 91 2001 8 1525 1529
27. A L Feldman L Tamarkin G F Paciotti Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clinical Cancer Research 6 2000 12 4628 4634
28. M Yamagata Y Shiratori Y Dan Serum endostatin levels in patients with hepatocellular carcinoma. Annals of Oncology 11 2000 6 761 762
29. J Góra-Tybor J Z Błoński T Robak Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators of Inflammation 12 2003 3 167 171
30. R Lai E Estey Y Shen Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer 94 2002 1 14 17